Member Info for Chelsea11

SB - agree it’s good to saw off your own leg if it has gangrene.

Essentially what this amounts to. What a strategic flop.

Common knowledge I think but don’t recall the actual link being posted here (published yesterday).

https://www.gov.uk/government/news/mhra-to-streamline-clinical-trial-approvals-in-biggest-overhaul-of-trial-regulation-in-20-years

…..by Motley Fool over the weekend.

I might fly over and see how big her smile is..

£5k top-up here.

Best of luck everyone.

To Berms point about waiting since 2015.

Mr Cossery’s influence perhaps? Or if the submission deadline date doesn’t align to his appointment, still an indication maybe that some eggs are beginning to hatch?

Think the Golden Cross needs a good polish

Redx posters indicated today (or so it seemed to me) that their treatment wasn’t expected to be the mutts nuts as a monotherapy but once combined with a CPI in future, the results could be very different. Also that this expectation had previously been communicated formally via Trinity Delta. I don’t know if I understood all that correctly but it did make me think that Scancell were not on those same rails based on news released to date. Perhaps one could say Very Encouraging:-)

Morning Chester.

I get your point but still believe it’s all there, in the body of the RNS (in fact VERY is mentioned). If folks are making investment decisions without reading down - well good luck with that!

Anyway, let’s hope there’s something far more interesting than our debate to look forward to this month :-)

At this stage of the trial, arguably more critically important than encouraging v. very encouraging, is the following RNS extract:

“well tolerated with no dose limiting toxicities”

Or would some prefer VERY well tolerated ;-)

For me, VERY just a play on words and not that significant in the headline messaging. Anyone who is looking to invest, top-up, sell, dance, panic, whatever will read down and get what they need. iMO of course.

Well then to quote ChippyJo from earlier today, directed to another poster……

“Accept your investment choices, or move on”

WTP. Guess it depends on your stance. Pushing back by just a few months to potentially realise greater benefits all round, might be an investment case consideration for some. It doesn’t mean the SP can’t rise as any positive news arrives ahead of any extension.

Is there a feasible scenario, where the CLN Redemption date is extended again? Early data has been described by the company / experts in their field as “encouraging”. So is it possible, with agreement, that the dates could be extended again, to allow more time for clinical data to be evaluated given the “encouragement?”

Watch this space indeed!

“This earnings accretive acquisition demonstrates Macfarlane's comprehensive 'buy and build' strategy in delivering further stakeholder value.”

Some may find this article interesting. Yes it’s lengthy and yes it’s a few years old but as you read down and hit the Jean-Michel Cossery name, you will understand why I’ve posted the link.

https://hbr.org/2010/10/unleashing-the-power-of-marketing

HAGW all.

Quite obviously all this intense debate about DTH can only mean one thing.

You wouldn’t want to be out of this over the weekend ;-)

Matt - do you believe the Company are able to make that kind of statement today?

Careful Krafty.

You’ll be in Ripley’s Sin Bin ;-)

SB - I'm also expecting something forward looking, that is tangible and breeds confidence.

Next news could be anything:

Statue of Elvis found on Mars
Bus found buried at South Pole
Woman gives birth to 8lb duck
Donkey robs Bank
Aliens turned our son into a fish finger
WW2 bomber found on the Moon
WW2 bomber found on the Moon vanishes

However I’ll go with SCIB1 update.